Cliniq s.r.o.
- Address
- lock Available on a paid plan
Digestive System Diseases
The Bratislava‑based facility is focusing on Ulcerative Colitis research, aiming to test new therapies that reduce bowel urgency and achieve endoscopic remission.
- Evaluation of an oral compound for improving ulcerative colitis symptoms
- Study of a monoclonal antibody targeting bowel urgency in ulcerative colitis
- Assessment of endoscopic improvement with a novel treatment
Cliniq s.r.o. currently manages eight clinical studies with eleven investigators, contributing to advances in Digestive System Diseases across Europe.
Immune System Diseases
Researchers are exploring innovative approaches for Atopic Dermatitis, including flexible dosing strategies to enhance skin clearance and maintain safety.
- Dose‑escalation trial of a JAK inhibitor for moderate to severe atopic dermatitis
- Investigation of dose reduction after achieving high skin response
- Safety monitoring of long‑term therapy in atopic dermatitis patients
With eight active trials, the site’s team of eleven investigators is advancing treatment options for Immune System Diseases in the region.
Musculoskeletal Diseases
The clinic conducts studies on Rheumatoid Arthritis, evaluating novel biologic agents to improve disease activity scores and patient outcomes.
- Investigation of a new biologic’s effect on joint inflammation
- Assessment of clinical response using standardized disease activity measures
- Comparison of treatment effectiveness versus standard care
Cliniq s.r.o.’s eight trials and eleven investigators reflect a strong commitment to progress in Musculoskeletal Diseases research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 30 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International7trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cliniq s.r.o.
lock Showing 1 of 46 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2) | Morphic Therapeutic Inc. | Phase II | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 30 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 7 | Unknown | 2019-10-19 | 2026-05-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.